What are the recommended treatment options for immune thrombocytopenia (ITP) refractory to prednisone?

Treatment of Prednisone-Refractory ITP in Adults

For adults with ITP unresponsive to prednisone, splenectomy remains the most effective second-line treatment with durable complete remissions in 66% of patients, though thrombopoietin receptor agonists (TPO-RAs) and rituximab are now viable alternatives depending on patient-specific factors. 1

Initial Assessment After Prednisone Failure

Before proceeding with second-line therapy, ensure the following have been evaluated:

• Test for secondary causes: Screen for HCV, HIV, and H. pylori infection, as these require specific management 1
• Confirm true steroid failure: Distinguish between non-response, steroid-dependence, or relapse after initial response 1
• Assess bleeding risk: Treatment intensity should match bleeding severity, not just platelet count 1, 2

Second-Line Treatment Algorithm

For Patients Who Can Undergo Surgery

Splenectomy is the recommended second-line treatment for patients who have failed corticosteroid therapy (Grade 1B recommendation). 1 This achieves:

• Complete response in 77.1% of patients 3
• Overall response rate of 91.4% 3
• Most durable remissions compared to other options 4
• Both laparoscopic and open approaches offer similar efficacy 1

Critical caveat: Delay splenectomy for at least 12 months when possible to allow for potential spontaneous remission, unless severe bleeding or quality of life issues necessitate earlier intervention 1

For Patients Avoiding or Deferring Splenectomy

The 2011 ASH guidelines provide two evidence-based alternatives:

Option 1: Thrombopoietin Receptor Agonists (TPO-RAs)

• May be considered after failing one line of therapy (corticosteroids or IVIG) without requiring splenectomy first (Grade 2C) 1
• Eltrombopag or romiplostim are both effective options for patients ≥3 months from diagnosis who are corticosteroid-dependent or non-responsive 1
• Particularly recommended for patients at risk of bleeding 1
• Effective as third-line treatment post-splenectomy failure, maintaining safe platelet counts in most patients 4

Option 2: Rituximab

• May be considered for patients at risk of bleeding who have failed one line of therapy (Grade 2C) 1
• Response rate of 71.4% with azathioprine showing 38.1% complete response in comparative studies 3
• Offers a viable alternative to splenectomy with less invasive approach 5
• Can be used after splenectomy failure as well 1

Comparative Effectiveness

The 2019 ASH guidelines addressed key comparative questions for patients ≥3 months from diagnosis who are corticosteroid-dependent or non-responsive 1:

• TPO-RA vs. Splenectomy: Both are acceptable; choice depends on surgical candidacy and patient preference 1
• Rituximab vs. Splenectomy: Splenectomy generally more effective but rituximab avoids surgical risks 1
• TPO-RA vs. Rituximab: Both are reasonable options; TPO-RAs may be preferred for maintaining platelet counts 1

Treatment Sequencing Strategy

Recommended sequence based on current evidence:

1. First attempt: Prednisone (failed in your case)
2. Second-line choice point:
   • If surgical candidate and willing: Splenectomy (most durable response) 1, 3
   • If avoiding surgery: TPO-RA (romiplostim or eltrombopag) OR rituximab 1
3. Third-line (if second-line fails):
   • If splenectomy failed: TPO-RA (Grade 1B recommendation) 1
   • If TPO-RA or rituximab failed: Consider splenectomy or alternative agent 1

Critical Pitfalls to Avoid

• Do not continue prolonged corticosteroid therapy: Minimize steroid exposure due to cumulative toxicity 5
• Do not treat asymptomatic patients with platelets >30 × 10⁹/L post-splenectomy: Observation is recommended 1
• Do not delay vaccination before splenectomy: Ensure pneumococcal, meningococcal, and H. influenzae vaccines are administered pre-operatively 1
• Do not ignore H. pylori: Eradication therapy should be administered if testing is positive (Grade 1B), as this may resolve ITP 1

Special Considerations

For patients with contraindications to splenectomy who have failed at least one other therapy: TPO-RAs are strongly recommended (Grade 1B) 1

Quality of life considerations: Treatment decisions should prioritize patient-specific outcomes including bleeding symptoms and quality of life, not just platelet counts 5

Emerging options: Fostamatinib (spleen tyrosine kinase inhibitor) is approved for refractory adult ITP and offers another alternative for patients failing multiple therapies 5